Boehringer Ingelheim (Canada) Ltd. v. Jamp Pharma Corporation, 2024 FC 656 (Nintedanib*)
Justice Furlanetto - 2024-05-02
Read full decision. Automatically generated summary:
This is a motion for reply evidence relating to an action under subsection 6(1) of the PM(NOC) Regulations. ... The proposed reply report of Dr. Bodmeier seeks to reply to thirteen paragraphs from the Gullapalli Responding Report and is allowed in part for the reasons set out below.
Decision relates to:
- T-1563-22 - BOEHRINGER INGELHEIM(CANADA) LTD ET AL v. JAMP PHARMA CORP.